Adverse functional effects of chemotherapy on whole-brain metabolism: A PET/CT quantitative analysis of FDG metabolic pattern of the "chemo-brain"

Clinical Nuclear Medicine

Volumn 39, Issue 1, 2014, Pages

  Sorokin, Jordan ^a   Saboury, Babak ^a   Ahn, JinHyung Albert ^a   Moghbel, Mateen ^a   Basu, Sandip ^a   Alavi, Abass ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Chemotherapy; FDG; Molecular imaging; Non Hodgkin lymphoma; PET; PET CT; SUV

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; GLUCOSE;

ADULT; AGED; ARTICLE; BRAIN CORTEX; BRAIN METABOLISM; BRAIN SIZE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG INDUCED DISEASE; FUNCTIONAL ASSESSMENT; FUNCTIONAL DISEASE; FUNCTIONAL NEUROIMAGING; GLUCOSE BRAIN LEVEL; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; IMAGING SOFTWARE; MIDDLE AGED; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PET-CT SCANNER; PILOT STUDY; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRAIN; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84891560571     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e318292aa81     Document Type: Article

References (32)

1. Griffin A, Butow P, Coates A, et al. On the receiving end V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol. 1996; 7:189-195
2. Love R, Leventhal H, Easterling D, et al. Side effects and emotional distress during cancer chemotherapy. Cancer. 1989;63:604-612
3. Markman M, Kennedy A, Kenneth W, et al. Neurotoxicity associated with a regimen of carboplatin (AUC 5-6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynecologic malignancies. J Cancer Res Clin Oncol. 2001;127:55-58
4. Gregg R, Molep J, Monpetit V, et al. Cisplatin neurotoxicity: The relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol. 1992;10:795-803
5. Vasterling J, Jenkins R, Tope D, et al. Cognitive distraction and relaxation training for the control of side effects due to cancer chemotherapy. J Behav Med. 1993;16:65-80
6. Silverman D, Dy C, Castellon S, et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-Treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat. 2007;103:303-311
7. Basu S, Kwee T, Surti S, et al. Fundamentals of PET and PET/CT imaging. Ann N Y Acad Sci. 2011;1228:1-18
8. Torigian DA, Lopez RF, Alapati S, et al. Feasibility and performance of novel software to quantify metabolically active volumes and 3D partial volume corrected SUV and metabolic volumetric products of spinal bone marrow metastases on 18F-FDG-PET/CT. Hell J Nucl Med. 2011;14:8-14
9. Basu S, Saboury B, Torigian DA, et al. Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: Emerging significance of image segmentation and global disease assessment. Mol Imaging Biol. 2011;13:801-11
10. Sandip B, Zaidi H, Houseni M, et al. Novel quantitative techniques for assessing regional and global function and structure based on modern imaging modalities: Implication for normal variation, aging, and diseased states. Semin Nucl Med. 2007;37:223-239
11. Mastro L, Costantini M, Morasso G, et al. Impact of two different doseintensity chemotherapy regimens on psychological distress in early breast cancer patients. Eur J Cancer. 2002;38:359-366
12. Moore BM, Copeland D, Ried H, et al. Neurophysiological basis of cognitive deficits in long-Term survivors of childhood cancer. Arch Neurol. 1992; 49:809-817
13. Ahles T, Saykin A. Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Invest. 2001;19:812-820
14. Shagen SB, van Dam FS, Muller MJ, et al. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 1999;85:640-650
15. Brezden C, Phillips K, Abdolell M, et al. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2000;18:2695-2701
16. Wefel J, Kayl A, Meyers C. Neuropsychological dysfunction associated with cancer and cancer therapies: A conceptual review of an emerging target. Br J Cancer. 2004;90:1691-1696
17. Inagaki M, Yoshikawa E, Matsuoka Y, et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer. 2006;109:146-156
18. Ferguson R, McDonald B, Saykin A, et al. Brain structure and function differences in monozygotic twins: Possible effects of breast cancer chemotherapy. J Clin Oncol. 2007;25:3866-3870
19. Tannock I, Ahles T, Ganz P, et al. Cognitive impairment associated with chemotherapy for cancer: Report of a workshop. J Clin Oncol. 2004;22:2233-2239
20. Baker SK, Lipson DM. Vincristine-induced peripheral neuropathy in a neonate with congenital acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2010;32:114-117
21. Tuxen M, Hansen S. Neurotoxicity secondary to antineoplastic drugs. Cancer Treat Rev. 1994;20:191-214
22. Awad A, Stüve O. Cyclophosphamide in multiple sclerosis: Scientific rational, history and novel treatment paradigms. Ther Adv Neurol Disord. 2009;2:50-61
23. Macdonell L, Potter P, Leslie R. Localized changes in blood-brain barrier permeability following the administration of antineoplastic drugs. Cancer Res. 1978;38:2930-2934
24. Drugbank.ca, Drug Bank: Open Data Drug & Drug Target Database 3.0. Recovered online October 28, 2011 at http://drugbank.ca/.
25. Kelder J, Grootenhuis D, Bayada D, et al. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm Res. 1999;16:1514-1519
26. Joshi S, Ergin A, Wang M, et al. Inconsistent blood brain barrier disruption by intraarterial mannitol in rabbits: Implications for chemotherapy. J Neurooncol. 2011;104:11-19
27. Hustinx R, Bénard R, Alavi A. Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med. 2002;32:35-46
28. Mikhaeel N, Hutchings M, Fields P, et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005;16:1514-1523
29. de Koning P, Jennekens F, Hispen W. Org.2766 protects from cisplatininduced neurotoxicity in rats. Exp Neurol. 2007;97:746-750
30. O' Shaughnessy J. Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy. Clin Breast Cancer. 2002;3:116-120
31. Cimprich B. Attentional fatigue following breast cancer surgery. Res Nurs Health. 2002;15:199-207
32. Komaki R, Meyers C, Shin D, et al. Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Int J Radiat Oncol Biol Phys. 1995;33:179-182